ESMO Preceptorship on Lung Cancer, 26-27 January 2024, Rabat, Morocco
Online application is now open until 14 December 2023
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Join us in Geneva or online to learn about recent developments in the field
An excellent opportunity for rare cancer researchers to interact and discuss the challenges around these complex cancers.
Stay up to date with the latest ESMO recommendations and discover for what type of advanced cancers it is advisable to perform tumour NGS.
Online application is now open until 14 December 2023
Let your research findings ignite discussions and help us drive progress in the breast cancer field
All late-breaking abstracts accepted for presentation at ESMO Asia 2023 as Proffered Papers or Mini Orals are now online!
How to apply the latest, best practice recommendations to your daily practice? Join this live discussion and get your questions answered by the ESMO Guidelines experts
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
Findings from the FLAURA2 study
Findings from the European MCL Elderly study
New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
ESMO advocates for stricter legislative measures for sunbed use in the EU to reduce the risks of melanoma
Findings from the TAB study
Evidence for efficacy is evaluated in CAPItello-291 study
Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
Increasing data show that they are indicators of inequitable environments which may negatively impact on cancer outcomes, but more efforts are needed to properly assess them in oncology
In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status
Green oriented practical tips encompass a reorganisation of waste disposal and pathology testing at single centres which may result in a reduction of the carbon footprint of cancer care globally
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
Promising results reported for datopotamab deruxtecan and trastuzumab deruxtecan in HER2-non-amplified breast cancer
Clinically meaningful improvements over standard care were observed in both first and second line, as reported in the MARIPOSA and MARIPOSA-2 phase III trials
However, lack of OS benefit limits the clinical impact of the findings from the PSMAfore trial
The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing
Findings from the FLAURA2 study
Findings from the European MCL Elderly study
New indications concerns a combination with enzalutamide for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
Findings from the TAB study
Evidence for efficacy is evaluated in CAPItello-291 study
Final results of a preplanned analysis at a 10-year follow-up of H10 study
Findings from an exploratory post hoc analysis of the subgroup of patients with BRCA alterations in PROfound study
Evidence for efficacy is based on the results from the FRESCO-2 and FRESCO studies
It is intended for the treatment of adults with advanced NSCLC with KRAS G12C mutation and disease progression after at least one prior systemic therapy
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumour cells, with less need for chemotherapy, following results of multiple landmark clinical trials reported for the first time in late-breaking presentations at the ESMO Congress 2023
Artificial intelligence (AI) has made a grand entrance into the public debate this year, but researchers have long been investigating its potential to transform cancer care and improve patient outcomes
Under the promise to “Disseminating innovative research for optimal cancer care” as this year’s tagline reads, the ESMO Congress 2023 will be held in Madrid between 20-24 October 2023 with a virtual component to allow as many people as possible to attend.
The ESMO Award for Immuno-Oncology 2023 was bestowed to Steven A. Rosenberg in recognition of his exceptional contribution to the field of cancer immunology research.
After five days filled with practice-changing data, intense discussions and educational sessions addressing the needs and issues currently arising for oncology professionals and impacting patients with cancer worldwide, the ESMO Congress 2023 today sent home its more than 33,000 participants from 144 countries with plenty of food for thought and ample material to enrich their medical practice.
ESMO and ASCO, the two largest professional organisations for oncologists, have released the 2023 edition of their joint recommendations for the Curriculum for Training in Medical Oncology
ESMO expresses deep sorrow about all the ongoing tragic events that continue to happen in many parts of the world and joins the voices pressing for a rapid return to peace
We regret to inform you of an embargo breach in which late-breaking abstract data has been made available online ahead of the official publication schedule
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
The very first expert-based guidance for reporting real-world evidence studies specifically for oncology, “ESMO Guidance for Reporting Oncology real-World evidence (GROW)", has been developed by ESMO, together with the valuable contribution of external stakeholders.
Committed to delivering high-quality medical science and to helping the oncology community to stay up to date with the latest developments in the field, ESMO has expanded its portfolio of journals.
From ESMO Congress 2023:
The use of docetaxel alongside FOLFOX chemotherapy significantly improves outcomes for patients with treatment-naïve, HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinoma
From ESMO Congress 2023:
Cabozantinib may offer a novel treatment option for patients with extra-pancreatic and pancreatic neuroendocrine tumours
From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.